Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of GRIFFIN (AFT-29)
- Citation:
- Blood vol 35 (Supplment 1) 48-49
- Meeting Instance:
- ASH 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Funding:
- AFT
- Endpoint:
- Primary
- Analysis:
- Long-Term-Followup
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3435
- Pharmas:
- Janssen Oncology
- Grants:
- Corr. Author:
- Authors:
- Peter M. Voorhees Cesar Rodriguez Brandi Reeves Nitya Nathwani Luciano J Costa Yana Lutska Cynthia Haines Daniela Hoehn Huiling Pei Jon Ukropec Ming Qi Thomas S Lin Paul G Richardson
- Networks:
- CA043, LAPS-AL002, LAPS-MA036, LAPS-NC007, LAPS-OH007, NC002
- Study
- AFT-29 (GRIFFIN)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: